StockNews.com Initiates Coverage on Jaguar Health (NASDAQ:JAGX)

StockNews.com assumed coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research report report published on Friday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Jaguar Health Trading Down 9.7 %

Shares of NASDAQ:JAGX traded down $0.50 during trading on Friday, reaching $4.63. 1,203,516 shares of the stock were exchanged, compared to its average volume of 1,006,360. The company has a quick ratio of 1.39, a current ratio of 1.89 and a debt-to-equity ratio of 1.84. Jaguar Health has a 12-month low of $3.07 and a 12-month high of $43.53. The firm’s 50-day moving average price is $9.61 and its 200 day moving average price is $9.94.

Jaguar Health (NASDAQ:JAGX) last announced its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($3.60) EPS for the quarter. Jaguar Health had a negative net margin of 377.95% and a negative return on equity of 642.15%. The firm had revenue of $2.35 million during the quarter. Equities analysts forecast that Jaguar Health will post -5.42 earnings per share for the current year.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.